Company intelligence / Profile preview

WuXi PharmaTech Investments

Shanghai, China

Ownership: Private
Employees: ~39000
Development stage: Other

Overview

WuXi AppTec serves 6,000+ customers across 30+ countries, providing integrated pharmaceutical R&D and manufacturing services. The company has established itself as a leading global CRDMO with operations spanning Asia, Europe, and North America

Therapeutic areas: OncologyEndocrinologyImmunologyInfectious Diseases
Modalities: Small moleculePeptidesOligonucleotidesAntibodyCAR-T cell therapyT-cell therapyMonoclonal antibodyVaccineViral vectorGene therapy
Industry: Drug Discovery Services

Partnerships

MedImmune/AstraZeneca (joint venture for MEDI5117)PRA International/PRA Health Sciences (clinical research joint venture)clients include GlaxoSmithKline, AstraZeneca, Pfizer, Jiangsu Hengrui

Beyond the preview

Go deeper on WuXi PharmaTech Investments.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WuXi PharmaTech Investments.

Explore the full profile